StemPoint Capital

Overview

StemPoint Capital is a private investment firm specializing in early-stage biotechnology investments. The firm focuses on sectors such as biotechnology, healthcare, pharmaceuticals, therapeutics, biopharma, clinical trials, and emergency medicine. It operates in the United States and Switzerland, targeting early-stage companies in these industries. StemPoint Capital's investment strategy involves identifying and supporting promising opportunities in the biotech and pharmaceutical sectors, aiming to generate absolute returns across various market cycles. The firm was founded and officially launched on January 3, 2023, by Michelle Ross, who brings nearly 20 years of investment management experience from esteemed firms like Soros Fund Management and PointState Capital. In January 2023, StemPoint Capital announced a strategic relationship with Leucadia Asset Management, a division of Jefferies Financial Group Inc., with Leucadia acquiring a minority economic interest in StemPoint. This partnership aims to leverage investment opportunities in the biotech and pharmaceutical sectors, enhancing StemPoint's ability to execute its investment strategy effectively. StemPoint Capital's portfolio includes investments in companies such as Spyre Therapeutics, Inc., a biotechnology firm focused on developing therapies for infectious diseases. The firm has also been involved in significant investments in other biotech companies, reflecting its commitment to advancing healthcare through strategic investments. The firm's approach combines growth aspects of the biotechnology sector with the defensive qualities of the pharmaceutical industry, seeking to generate absolute returns in varying market cycles. This strategy is supported by StemPoint's experienced team, led by Michelle Ross, who has a strong background in investment management and a deep understanding of the biotech and pharmaceutical industries. The firm's strategic relationship with Leucadia Asset Management is expected to provide additional resources and expertise, further strengthening StemPoint Capital's position in the market. This partnership is part of StemPoint's broader strategy to expand its reach and impact in the biotechnology sector, aiming to identify and support the most promising opportunities in the industry. The collaboration with Leucadia Asset Management is anticipated to enhance StemPoint's ability to execute its investment strategy and achieve its objectives in the evolving biotech landscape.

Investment Focus

• Early-stage biotechnology companies
• Focus on stem cell and regenerative medicine

Portfolio Companies